Abstracts Archive - Page 2335 of 2425 - ACR Meeting Abstracts

Abstract Number: 1305 • 2012 ACR/ARHP Annual Meeting
Three-Year Follow-up of Rituximab in Rheumatoid Arthritis: Results From the Belgian MIRA (MabThera in Rheumatoid Arthritis) Registry
Filip De Keyser¹, Patrick Durez², Rene Westhovens³, marie-Joelle Kaiser⁴ and Ilse Hoffman⁵, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ³Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ⁴Rheumatology, Dept Rheumatology, University Hospital Liege, Belgium, Belgium, ⁵Rheumatology, Dept Rheumatology, GZA St-Augustinus Hospital Antwerp, Belgium, Wilrijk, Belgium
Background/Purpose: The MIRA registry was set up to collect safety, efficacy and (re)treatment practice data for Belgian RA patients treated with rituximab. Methods: All rheumatologists…
Abstract Number: 1306 • 2012 ACR/ARHP Annual Meeting
How well Do Patients with Rheumatoid and Psoriatic Arthritis Tolerate Methotrexate? A Retrospective Review of Discontinuation Data From a Large UK Cohort
Calum T. Goudie¹, John D. Fitzpatrick¹, Anshuman P. Malaviya² and Andrew J. Ostor², ¹University of Cambridge Medical School, Cambridge, United Kingdom, ²Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and safety, methotrexate (MTX) has become the first-line disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA). Although deemed safe,…
Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
Steven De Bruyn¹, Béla Gachályi², Bernadette Rojkovich³, Slavomir Bruk⁴, Petr Sramek⁵, Mariusz Korkosz⁶, Krzysztof Krause⁷, Pieter Schoen⁸, Laura Sargentini-Maier⁹, Joke D'Artois¹⁰, Katrien Verschueren¹⁰, Katelijne De Swert¹⁰, Gerhard Arold¹¹ and Josefin-Beate Holz¹², ¹Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ²Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, ³II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, ⁴Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, ⁵Pharmaceutical Research Associates CZ, Praha, Czech Republic, ⁶Malopolskie Centrum Medyczne, Krakow, Poland, ⁷Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, ⁸Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁹Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ¹⁰Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ¹¹Medical Affairs, PRA International GmbH, Berlin, Germany, ¹²Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
Abstract Number: 1308 • 2012 ACR/ARHP Annual Meeting
Opportunistic Infections in Patients with Rheumatoid Arthritis Treated with Rituximab : Data From the Autoimmunity and Rituximab Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Thomas Bardin³, Patrice Cacoub⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Xavier X. Le Loet¹¹, Eric Hachulla¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Gabriel Baron¹⁶ and Xavier Mariette¹⁷, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁶Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹¹Rheumatology Department, CHU de ROUEN, Rouen, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology, Strasbourg, France, ¹⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Therapy with biological agents may be associated with opportunistic infections (OIs). Data on the occurrence of OIs in patients with RA treated with rituximab…
Abstract Number: 1309 • 2012 ACR/ARHP Annual Meeting
Predictive Risk Factors of Serious Infections in RA Patients Treated with Abatacept in Real Life: Results in the Orencia and Rheumatoid Arthritis (ORA) Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Alain G. Cantagrel³, Bernard Combe⁴, René-Marc Flipo⁵, Thierry Schaeverbeke⁶, Eric Houvenagel⁷, Philippe Gaudin⁸, Damien Loeuille⁹, Stephanie Rist¹⁰, Maxime Dougados¹¹, Jean Sibilia¹², Xavier Le Loet¹³, Christian Marcelli¹⁴, Thomas Bardin¹⁵, Isabelle Pane¹⁶, Elodie Perrodeau¹⁷, Gabriel Baron¹⁸ and Xavier Mariette¹⁹, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁴Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁵Rheumatology Department, Lille University Hospital, Lille, France, ⁶Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁷Service de Rhumatologie, St Philibert Hospital, Lomme 59462, France, ⁸Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁹Rheumatology, CHU Brabois, Vandoeuvre les Nancy, France, ¹⁰Hospital University Orléans, France, ¹¹Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ¹²Rheumatology, CHU Hautepierre, Strasbourg, France, ¹³Rheumatology Department, CHU de ROUEN, Rouen, France, ¹⁴Rheumatology Department, Caen University Hospital, ¹⁵Rheumatology, Hôpital Lariboisière, Paris, France, ¹⁶Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁷Epidemiologist, Paris, France, ¹⁸Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ¹⁹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Little data is available regarding the rate and predicting factors of serious infections in patients with rheumatoid arthritis treated with abatacept (ABA) in daily…
Abstract Number: 1310 • 2012 ACR/ARHP Annual Meeting
Analysis of Anti-JC Polyomavirus T-Cell Immune Response with JC-Feron in Patients with Rheumatoid Arthritis Treated with Rituximab or Anti-TNF
Raphaèle Seror¹, Houria Chavez², anne-Aurélie Mazet³, Jeremie Sellam⁴, Bruno Fautrel⁵, Maxime Dougados⁶, Yassine Taoufik² and Xavier Mariette⁷, ¹Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ²Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, ³Virology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁴Rheumatology, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 75012, France, ⁵Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁶Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Some cases of progressive multifocal leukoencephalopathy (PML) have been described in patients with autoimmune diseases with profound immunosuppression, due to replication of JC polyomavirus…
Abstract Number: 1311 • 2012 ACR/ARHP Annual Meeting
A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate
Roy Fleischmann¹, Steven De Bruyn², Christian Duby², Katrien Verschueren³, Judith Baumeister⁴, Laura Sargentini-Maier⁵, Cedric Ververken⁶ and Josefin-Beate Holz⁷, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ³Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ⁴Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ⁵Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ⁶Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁷Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Ozoralizumab (ATN-103), a novel TNFα inhibitor, is a trivalent, bispecific Nanobody® that potently neutralises TNF and binds to human serum albumin to increase its…
Abstract Number: 1312 • 2012 ACR/ARHP Annual Meeting
Clinical Response At 12 Weeks Predicts Long-Term Remission and the Extent of Radiographic Progression in Japanese Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol with and without Methotrexate Coadministration
Tsutomu Takeuchi¹, Kazuhiko Yamamoto², Hisashi Yamanaka³, Naoki Ishiguro⁴, Yoshiya Tanaka⁵, Katsumi Eguchi⁶, Akira Watanabe⁷, Hideki Origasa⁸, Toshiharu Shoji⁹, Nobuyuki Miyasaka¹⁰ and Takao Koike¹¹, ¹Keio University School of Medicine, Tokyo, Japan, ²Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁵The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶Sasebo City General Hospital, Sasebo, Nagasaki, Japan, ⁷Research Division for Development of Anti-Infectious Agents, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan, ⁸Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁹Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, ¹⁰Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹Sapporo medical center NTT EC, Sapporo, Japan
Background/Purpose: The majority of patients (pts) with active rheumatoid arthritis (RA) have previously been shown to respond during the first 12 weeks (wks) of certolizumab…
Abstract Number: 1313 • 2012 ACR/ARHP Annual Meeting
Tolerance of Rituximab in Patients with a History of Cancer : Data From the Registry Air
Jacques-Eric Gottenberg¹, Marie-Odile Duzanski², Thomas Bardin³, Patrice Cacoub⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Eric Hachulla¹¹, Xavier Le Loet¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Philippe Ravaud¹⁶, Gabriel Baron¹⁷ and Xavier Mariette¹⁸, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Service Pharmacie - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Dept of Rheumatology, Hopital Purpan, Toulouse CEDEX 9, France, ⁶Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹¹Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹²Rheumatology Department, CHU de ROUEN, Rouen, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁷Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ¹⁸Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Data regarding tolerance of biologics in patients with a history of cancer are very limited. We therefore analyzed tolerance of rituximab (RTX) in patients…
Abstract Number: 1314 • 2012 ACR/ARHP Annual Meeting
Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients
Tsukasa Matsubara¹, Satoru Koyano², Keiko Funahashi², James E. Middleton², Takako Miura¹, Kosuke Okuda¹, Takeshi Nakamura¹, Akira Sagawa³, Takeo Sakurai⁴, Hiroaki Matsuno⁵, Tomomaro Izumihara⁶, Eisuke Shono⁷, Kou Katayama⁸, Toyomitsu Tsuchida⁹, Mitsuyoshi Iwahashi¹⁰, Tomomi Tsuru¹¹ and Motohiro Oribe¹², ¹Matsubara Mayflower Hospital, Kato, Japan, ²Research Institute of Joint Diseases, Kobe, Japan, ³Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ⁴Inoue Hospital, Takasaki, Japan, ⁵Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁶Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, ⁷Shono Rheumatology Clinic, Fukuoka, Japan, ⁸Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ⁹Tsuchida Clinic, Chiba, Japan, ¹⁰Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, ¹¹PS Clinic, Fukuoka, Japan, ¹²Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan
Background/Purpose: Achievement of remission or low disease activity with infliximab (IFX) and etanercept (ETN) treatment is currently one of the most important matters in RA…
Abstract Number: 1315 • 2012 ACR/ARHP Annual Meeting
Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tabalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis
Wendy J. Komocsar¹, Mark C. Genovese², Ernst R. Dow³, Poulabi Banerjee¹, Michelle A. Penny³, Eric P. Nantz¹, Sergey Stepaniants⁴, Anne Ho⁴, Pierre-Yves Berclaz¹ and Robert W. Hoffman¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Division of Rheumatology, Stanford University, Palo Alto, CA, ³Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, ⁴Covance Genomics Laboratory LLC, Seattle, WA
Background/Purpose: Tabalumab, a monoclonal antibody neutralizing membrane bound and soluble B cell activating Factor (BAFF), has been shown to reduce the signs and symptoms of…
Abstract Number: 1276 • 2012 ACR/ARHP Annual Meeting
Changes in B Cell Populations and Serum Immunoglobulins and Their Relationship to Infections in a One Year, Uncontrolled Open Label Study of Tabalumab
Maria W. Greenwald¹, Melissa Veenhuizen², Wendy Komocsar³, Rebecca Jones-Taha⁴, Chin H. Lee³ and Pierre-Yves Berclaz³, ¹Desert Medical Advances, Palm Desert, CA, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly & Company, Indianapolis, IN, ⁴PharmaNet/i3, Blue Bell, PA
Background/Purpose: B cell activating factor (BAFF) is an important modulator of B cell development and proliferation and is secreted by neutrophils, monocytes, macrophages and dendritic…
Abstract Number: 1277 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
D. van der Heijde¹, Y. Tanaka², Roy Fleischmann³, Edward Keystone⁴, Joel M. Kremer⁵, C. Zerbini⁶, M. H. Cardiel⁷, S. B. Cohen⁸, P. T. Nash⁹, Y. Song¹⁰, D. Tegzova¹¹, B. Wyman¹², D. Gruben¹², B. Benda¹³, G. Wallenstein¹⁴, S. Krishnaswami¹², S. H. Zwillich¹², J. Bradley¹⁵, C. A. Connell¹⁶ and ORAL Scan Investigators¹⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁵The Center for Rheumatology, Albany Medical College, Albany, NY, ⁶CEPIC – Centro Paulista de Investigação Clínica, São Paulo-SP, Sao Paulo, Brazil, ⁷Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁸Metroplex Clinical Research Centre, Dallas, TX, ⁹Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia, ¹⁰Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Pfizer Inc., Groton, CT, ¹³Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ¹⁴Pfizer Inc, New York, NY, ¹⁵Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ¹⁶Pfizer Inc, Groton, CT, ¹⁷Groton
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This 24‑month (Mo) Phase 3…
Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting
Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Kevin L. Winthrop¹, S.-H. Park², A. Gul³, M. Cardiel⁴, JJ Gomez-Reino⁵, D. Ponce de Leon⁶, R. Riese⁷, R. Chew⁷, T. Kawabata⁷, E. Mortensen⁶ and H. Valdez⁸, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²The Catholic University of Korea, Seoul, South Korea, ³Istanbul University, Istanbul, Turkey, ⁴Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁵Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Pfizer Inc., Collegeville, PA, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., New York, NY
Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…
Abstract Number: 1279 • 2012 ACR/ARHP Annual Meeting
First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis
Stanislav Ignatenko¹, Birte K. Skrumsager², Adam Steensberg³ and Ulrik Mouritzen³, ¹Charité Research Organization GmbH, Berlin, Germany, ²Clinical Pharmacology Biopharm, Novo Nordisk A/S, Copenhagen, Denmark, ³Medical & Science, Inflammation, Novo Nordisk A/S, Copenhagen, Denmark
Background/Purpose: Interleukin-21 (IL-21), a cytokine produced by activated T cells (especially T17 and TFH cells), has a proinflammatory and pleiotropic nature, and drives mainly activation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].